Which treatments are currently available for relapsed and refractory myeloma treatment?
Naveen Pemmaraju: what to look out for at ASH 2016
Comparison of native vs pegylated asparaginase for HR Ph chromosome-negative ALL
Next steps for Hodgkin lymphoma - combining brentuximab vedotin with checkpoint inhibitors
MPN Landmark studies: looking at the disparities in perceptions of disease and treatment preferences